Citation:Otterson GA, Hodgson L, Pang H, Vokes EE, Cancer and Leukemia Group B 2010

From Cancer Guidelines Wiki

Citation


Otterson GA, Hodgson L, Pang H, Vokes EE, Cancer and Leukemia Group B. Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). J Thorac Oncol 2010 Oct;5(10):1644-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/20871263.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACPcompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?